Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -22% Improvement Relative Risk Ventilation 85% Progression, day 15 76% Progression, day 7 39% Recovery 100% primary c19early.com/aa Ghandehari et al. NCT04365127 Antiandrogens RCT LATE Favors antiandrogen Favors control
Ghandehari, 40 patient antiandrogen late treatment RCT: 85% lower ventilation [p=0.24], 76% lower progression [p=0.2], and 100% improved recovery [p=0.02] https://c19p.org/ghandehari
copied to clipboard
Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19
31 Jul 2021    Source   PDF   Share   Tweet
RCT 42 hospitalized patients in the USA, showing improved recovery and lower progression with progesterone treatment.
risk of death, 22.2% higher, RR 1.22, p = 1.00, treatment 1 of 18 (5.6%), control 1 of 22 (4.5%), day 15.
risk of mechanical ventilation, 84.5% lower, RR 0.15, p = 0.24, treatment 0 of 18 (0.0%), control 3 of 22 (13.6%), NNT 7.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), peak value day 7 and 15.
risk of progression, 75.6% lower, RR 0.24, p = 0.20, treatment 1 of 18 (5.6%), control 5 of 22 (22.7%), NNT 5.8, day 15.
risk of progression, 38.9% lower, RR 0.61, p = 0.48, treatment 3 of 18 (16.7%), control 6 of 22 (27.3%), NNT 9.4, day 7.
relative recovery, 100% better, RR <0.001, p = 0.02, treatment 18, control 22, relative change in status, day 7, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ghandehari et al., 31 Jul 2021, Randomized Controlled Trial, USA, peer-reviewed, mean age 55.3, 14 authors, study period April 2020 - August 2020, trial NCT04365127 (history).
Contact: sara.ghandehari@cshs.org.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit